Dr. Anders Høgset Profile

Dr. Anders Høgset

at PCI Biotech AS

SPIE Involvement:

Author

Publications (2)

This will count as one of your downloads.

You will have access to both the presentation and article (if available).

DOWNLOAD NOW

This content is available for download via your institution's subscription. To access this item, please sign in to your personal account.

Email or Username Forgot your username?

Password Forgot your password?

Show

Keep me signed in

No SPIE account? Create an account

Proceedings Article | 14 August 2019 Presentation

Review of photochemical internalisation (PCI) applications (Conference Presentation)

Anders Høgset, Per Walday

Proceedings Volume 11070, 110703B (2019) https://doi.org/10.1117/12.2528406

KEYWORDS: Molecules, Proteins, Cancer, Nanoparticles, Pathogens

Read Abstract +

The Photochemical internalization (PCI) PCI technology can be used for enhancing the intracellular delivery of many different types of molecules with therapeutic activity or therapeutic potential. Clinical studies are on-going with the use of PCI for improving the effect of a cancer chemotherapeutic agent, as well as for evaluation of the potential of PCI for enhancing the effect of vaccination with peptide and protein antigens. The application of PCI in these areas will be discussed. In addition to the applications already in clinical development the PCI technology also has a large potential for the use in other therapeutic areas. Thus, in preclinical studies very interesting results have been achieved using PCI for the delivery of various types of nucleic acids, with especially interesting results for mRNA delivery. mRNA are molecules with a very interesting therapeutic potential if the current delivery problems could be solved, and pre-clinical results indicate that PCI may contribute to solving these problems for several potential uses of mRNA-based therapeutics. PCI has also shown very promising results with protein-based cytotoxic agents such as protein toxins and immunotoxins, as well as for drug delivery mediated by various types of nanoparticles. Recently, it has also been shown that PCI can enhance the intracellular delivery of certain antibiotic agents, with a potential to treat local infections with intracellular pathogens. Key pre-clinical findings in these areas will be presented, and current and potential clinical uses of the PCI technology will be discussed.

Proceedings Article | 14 August 2019 Presentation

Phase I clinical study for validation of photochemical internalisation (fimaVacc): a novel technology for enhancing cellular immune responses important for therapeutic effect of peptide- and protein-based vaccines (Conference Presentation)

Anders Høgset, Anne Grete Nedberg, Victoria Edwards, Monika Håkerud, Hans Olivecrona, Tone Otterhaug

Proceedings Volume 11070, 110703P (2019) https://doi.org/10.1117/12.2526042

KEYWORDS: Proteins, Receptors, Flow cytometry

Read Abstract +

In the fimaVacc technology photochemical internalization (PCI) is employed for enhancing cytotoxic T-cell responses to vaccination. Thus, in pre-clinical studies fimaVacc has been shown to increase MHC class I antigen presentation, leading to strongly enhanced cytotoxic- and helper T-cell responses to various types of vaccines. On the basis of promising preclinical results, a phase I clinical study with fimaVacc has been performed in healthy volunteers. FimaVacc involves formulating the vaccine with a photosensitising compound (fimaporfin) and a toll-like receptor (TLR) agonist. The vaccine is given as intradermal injections followed by illumination of the vaccination site. Results from a phase I clinical study in healthy volunteers will be presented. The subjects were vaccinated with models for peptide- and protein-based vaccines; HPV16 E7 peptide antigens and Keyhole Limpet Hemocyanin. Both antigens were formulated with the TLR3 agonist poly-ICLC (Hiltonol), and up to three vaccinations were be given. Local and systemic adverse effects will be assessed, and cellular and humoral immune responses were analysed by ELISPOT and ELISA assays, and by flow cytometry.

My Library

You currently do not have any folders to save your paper to! Create a new folder below.

Folder Name

Folder Description

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks. You are receiving this notice because your organization may not have SPIE eBooks access.*

*Shibboleth/Open Athens users─please sign in to access your institution's subscriptions.

To obtain this item, you may purchase the complete book in print or electronic format on SPIE.org.

ORGANIZATIONAL
Sign in with credentials provided by your organization.

Organizational Username

Organizational Password

Show/Hide Password

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members:

Non-members: ADD TO CART

Keywords/Phrases

Search In:

Publication Years